NuCana PLC (NCNA) intrinsic value & 10-year financials

NuCana PLC (NCNA) has no Graham intrinsic value right now because the formula needs positive earnings.

Graham intrinsic value
—
Share price (Oct 20, 2026)
$1.01
Revenue (FY2025)
—
ROIC (10-yr avg)
-73.6%
Free cash flow (FY2025)
—

NCNA 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 — -$29.4M — — — -193.9%
FY2024 — -$19.0M — -$19.1M — -182.3%
FY2023 — -$27.6M — -$26.4M — -103.5%
FY2022 — -$32.0M — -$23.2M — -61.5%
FY2021 — -$40.5M — -$23.9M — -49.2%
FY2020 — -$30.7M — -$22.0M — -37.7%
FY2019 — -$21.4M — -$23.9M — -29.5%
FY2018 — -$13.8M — -$12.4M — -15.8%
FY2017 — -$23.1M — -$9.1M — -38.9%
FY2016 — -$6.0M — -$9.3M — -24.0%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

NuCana plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

NuCana plc has historically struggled to out-earn its cost of capital, averaging just -36.4% ROIC.

NuCana plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

NuCana plc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.

NCNA stock: frequently asked questions

What is NCNA's return on invested capital?

Average ROIC over the last 10 fiscal years was -73.6%, and average return on equity was -73.6%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this NCNA data come from?

From NuCana PLC's annual 10-K filings on SEC EDGAR, most recently filed Mar 19, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks